Paper42007156
The impact of anti-vascular endothelial growth factor therapy on the activation status of retinal macrophages/microglia in patients with diabetic retinopathy and familial exudative vitreoretinopathy and its association with treatment response.
Li J and 5 others. Am J Transl Res, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. The impact of anti-vascular endothelial growth factor therapy on the activation status of retinal macrophages/microglia in patients with diabetic retinopathy and familial exudative vitreoretinopathy and its association with treatment response. Papers, record 42007156. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42007156
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
The impact of anti-vascular endothelial growth factor therapy on the activation status of retinal macrophages/microglia in patients with diabetic retinopathy and familial exudative vitreoretinopathy and its association with treatment response.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36254977 | Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. | Neural Regen Res | 2023 | https://conductscience.org/library/papers/36254977 | PubMed |
| 2 | 39367441 | Insights to Ang/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases. | J Transl Med | 2024 | https://conductscience.org/library/papers/39367441 | PubMed |
| 3 | 39914485 | Anatomic Control with Faricimab versus Aflibercept in the YOSEMITE/RHINE Trials in Diabetic Macular Edema. | Ophthalmol Retina | 2025 | https://conductscience.org/library/papers/39914485 | PubMed |
| 4 | 38250154 | Angiogenic and Fibrogenic Dual-effect of Gremlin1 on Proliferative Diabetic Retinopathy. | Int J Biol Sci | 2024 | https://conductscience.org/library/papers/38250154 | PubMed |
| 5 | 37404990 | Retinal glia and NF-κB in diabetic retinopathy pathogenesis. | Ann Transl Med | 2023 | https://conductscience.org/library/papers/37404990 | PubMed |
| 6 | 39388397 | Optimization of individualized faricimab dosing for patients with diabetic macular edema: Protocol for the SWAN open-label, single-arm clinical trial. | PLoS One | 2024 | https://conductscience.org/library/papers/39388397 | PubMed |
| 7 | 38592149 | The Treatment of Diabetic Retinal Edema with Intravitreal Steroids: How and When. | J Clin Med | 2024 | https://conductscience.org/library/papers/38592149 | PubMed |
| 8 | 39882395 | Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study. | Clin Ophthalmol | 2025 | https://conductscience.org/library/papers/39882395 | PubMed |
| 9 | 37482199 | Activation of aryl hydrocarbon receptor by azatyrosine-phenylbutyric hydroxamide inhibits progression of diabetic retinopathy mice. | Biochem Pharmacol | 2023 | https://conductscience.org/library/papers/37482199 | PubMed |
| 10 | 37007562 | Inhibition of NF-κB ameliorates aberrant retinal glia activation and inflammatory responses in streptozotocin-induced diabetic rats. | Ann Transl Med | 2023 | https://conductscience.org/library/papers/37007562 | PubMed |
| 11 | 38892258 | The Severity of Diabetic Retinopathy Corresponds with Corneal Nerve Alterations and Ocular Discomfort of the Patient. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38892258 | PubMed |
| 12 | 36736895 | Longitudinal Quantitative Ultrawide-field Fluorescein Angiography Dynamics in the RUBY Diabetic Macular Edema Study. | Ophthalmol Retina | 2023 | https://conductscience.org/library/papers/36736895 | PubMed |
| 13 | 39031809 | Innovative Nanotechnology in Drug Delivery Systems for Advanced Treatment of Posterior Segment Ocular Diseases. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/39031809 | PubMed |
| 14 | 38626646 | Genipin ameliorates diabetic retinopathy via the HIF-1α and AGEs-RAGE pathways. | Phytomedicine | 2024 | https://conductscience.org/library/papers/38626646 | PubMed |
| 15 | 40180022 | Nitric oxide mediates negative feedback on the TXNIP/NLRP3 inflammasome pathway to prevent retinal neurovascular unit dysfunction in early diabetic retinopathy. | Free Radic Biol Med | 2025 | https://conductscience.org/library/papers/40180022 | PubMed |
| 16 | 39658713 | Visual and anatomical failure of anti-VEGF therapy for retinal vascular diseases: a survival analysis of real-world data. | Eye (Lond) | 2025 | https://conductscience.org/library/papers/39658713 | PubMed |
| 17 | 39260060 | Heme: A link between hemorrhage and retinopathy of prematurity progression. | Redox Biol | 2024 | https://conductscience.org/library/papers/39260060 | PubMed |
| 18 | 38918759 | Therapeutic intervention in neuroinflammation for neovascular ocular diseases through targeting the cGAS-STING-necroptosis pathway. | J Neuroinflammation | 2024 | https://conductscience.org/library/papers/38918759 | PubMed |
| 19 | 36984630 | Optical Coherence Tomography Biomarkers in Predicting Treatment Outcomes of Diabetic Macular Edema after Ranibizumab Injections. | Medicina (Kaunas) | 2023 | https://conductscience.org/library/papers/36984630 | PubMed |
| 20 | 37481454 | The additive effect of intravitreal dexamethasone combined with bevacizumab in refractory diabetic macular edema. | J Fr Ophtalmol | 2023 | https://conductscience.org/library/papers/37481454 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42720425 | Structural and Angiographic Assessment of the Nerve Fiber Layer in Age-Related Macular Degeneration and Diabetic Retinopathy. | Invest Ophthalmol Vis Sci | 2026 | https://conductscience.org/library/papers/42720425 |
Source PubMed
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IL10 | 3586 | PubTator's text mining | https://conductscience.org/library/genes/3586 | NCBI Gene |
| IL1B | 3553 | PubTator's text mining | https://conductscience.org/library/genes/3553 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
| VEGFA | 7422 | PubTator's text mining | https://conductscience.org/library/genes/7422 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42007156
GET https://conductscience.org/api/papers/v1/42007156/references?page=2